Home/Pipeline/New GI Formulation

New GI Formulation

Undisclosed Gastrointestinal Disease

Phase II/IIIActive

Key Facts

Indication
Undisclosed Gastrointestinal Disease
Phase
Phase II/III
Status
Active
Company

About Zeria Pharmaceutical

Zeria Pharmaceutical's mission is to contribute to human health through the development and provision of high-quality pharmaceutical and healthcare products. The company has achieved a robust market position in Japan, particularly in gastroenterology, and has built a sustainable business model through a diversified portfolio spanning prescription drugs, OTC products, and nutraceuticals. Its strategy focuses on lifecycle management of core assets, strategic in-licensing, and targeted expansion into high-growth Asian consumer health markets. Zeria's financial strength, evidenced by its significant market cap, supports steady R&D investment and strategic partnerships.

View full company profile